Developer docs
API playgroundTry for free, no card

Search company profiles

Piramal Pharma

Full company profile

uuid00ajan7

Namestring
Piramal Pharma
Legal namestring
Piramal Pharma Limited
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Piramal Pharma Limited is a publicly listed (BSE/NSE ticker PPL) global pharmaceutical company headquartered in Mumbai, India, operating across four segments: Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a hospital generics and inhaled anesthetics franchise; Piramal Consumer Healthcare (PCH), an India-focused OTC business with brands such as Little's, Lacto Calamine, i-pill, Tetmosol, and Polycrol; and a joint venture with AbbVie in ophthalmic therapeutics.

The CDMO segment, which contributed approximately 55% of revenue, operates a network of 17 globally integrated development and manufacturing facilities across India, the United States, the United Kingdom, and Canada, offering end-to-end services from API synthesis and peptide manufacturing through formulation development and sterile fill-finish. Differentiated technical capabilities include the ADCelerate platform for accelerated antibody-drug conjugate (ADC) development, the Grangemouth UK facility — the first FDA-approved ADC CDMO globally with 1,500 batches delivered — specialized payload-linker manufacturing at Riverview, Michigan, Band 5 HPAPI containment, and proprietary digital platforms (eLab, exForms, iAssist) supported by an enterprise-wide Project Catalyst NxGen ERP transformation.

The company generates revenue through contract-based development fees and commercial supply agreements in CDMO, hospital-channel sales of generics and anesthetics in Critical Care, and Indian retail/e-commerce distribution in Consumer Healthcare. FY26 disclosed revenue was ₹8,869 crore, with management publicly targeting a doubling to approximately $2 billion by FY30. Key customers disclosed include Botanix SB Inc., NewAmsterdam Pharma, Plus Therapeutics, Bolt Biotherapeutics, Theracosbio, and Theratechnologies, alongside strategic co-development partnerships with Ajinomoto Bio-Pharma, IntoCell, and Blue-Zone Technologies.

Short descriptiontext

Piramal Pharma Limited is a global pharmaceutical company operating a CDMO (Piramal Pharma Solutions), an inhaled anesthetics and hospital generics business (Piramal Critical Care), and an India-focused OTC consumer healthcare division (Piramal Consumer Healthcare), serving pharma innovators, hospitals, and Indian consumers across 17 facilities in 100+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices18 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, drug development services, inhaled anesthetics, consumer healthcare products, antibody drug conjugates
Industry3 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing and CDMO Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharma Solutions (CDMO)
TypeProfessional Services
Description

Contract Development and Manufacturing Organization providing end-to-end drug development and manufacturing services to pharmaceutical innovators. Revenue generated through service contracts, development fees, and commercial manufacturing supply agreements. Represents the largest revenue segment at approximately 55% of total revenue.

piramalpharma.com
2Critical Care
TypeOne Time License
Description

Hospital generics business focused on inhaled anesthetics and critical care medications. Products sold to hospitals and healthcare facilities globally through direct sales and distribution partnerships.

piramalpharma.com
3Consumer Healthcare
TypeOne Time License
Description

India-focused consumer healthcare business with established OTC brands including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri-Activ. Revenue from product sales through retail distribution channels.

piramalpharma.com
4Complex Hospital Generics
TypeOne Time License
Description

Complex hospital generics including injectables and specialized pharmaceutical products. Growth segment including the Kenalog brand acquisition for hospital-based therapies.

simplywall.st
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Piramal Pharma Solutions
Description

Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug lifecycle

piramalpharma.com
+3 more records
Core offering1 text field

Piramal Pharma is a global integrated pharmaceutical company providing end-to-end contract development and manufacturing (CDMO) services, critical care pharmaceuticals including inhalation anesthetics and injectables, and consumer healthcare OTC products. The company serves top 20 biopharma companies, global hospital networks, and retail consumers through 17 manufacturing facilities across India, the US, the UK, and Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Delivered over 70 regulatory approvals across global network in single fiscal year
+4 more records
Product overview1 text field

Piramal Pharma Limited operates as a diversified global pharmaceutical company with four distinct business segments: Piramal Pharma Solutions (PPS) as a Contract Development and Manufacturing Organization offering end-to-end drug development and manufacturing services; Piramal Critical Care (PCC) specializing in inhaled anesthetics and hospital generics; Piramal Consumer Healthcare (PCH) with established OTC brands including Little's, Lacto Calamine, i-pill, Tetmosol, Polycrol, Tri-Activ, and i-choose; and AbbVie Therapeutics India for ophthalmic products. The company also operates the ADCelerate platform for rapid integrated ADC development. PPS maintains facilities across North America, Europe, and Asia, providing services from API synthesis through finished dosage manufacturing, with digital platforms including eLab, exForms, and iAssist supporting quality and compliance operations.

Product and service4 records
1Piramal Pharma Solutions (CDMO Services)
CategoryContract Development and Manufacturing Services (CDMO)
Description

End-to-end contract development and manufacturing organization (CDMO) services for global biopharma companies, covering drug substance and drug product development, manufacturing, and commercialization across small molecules, biologics, and antibody-drug conjugates. Customers include top 20 biopharma companies.

2Piramal Critical Care
CategoryCritical Care Pharmaceuticals
Description

Critical care pharmaceutical products including inhalation anesthetics and injectable products sold to hospitals, healthcare institutions, and government health systems globally. The company is among the global leaders in inhalation anesthesia products.

3Piramal Consumer Healthcare
CategoryConsumer Healthcare / OTC Products
Description

Over-the-counter (OTC) consumer healthcare and personal care brands sold through retail pharmacy chains and modern trade in India, including established brands such as Lacto Calamine and Jungle Magic.

4AbbVie Therapeutics India (Joint Venture)
CategoryPharmaceutical Distribution (India)
Description

Joint venture with AbbVie for the sale and distribution of AbbVie's pharmaceutical products in the Indian market, leveraging Piramal's established India sales and distribution infrastructure.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Manufacturing and supply arrangement to develop and validate Sofpironium Bromide at Piramal's Riverview, Michigan facility with optional validation at its Aurora, Canada facility

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Joint development of Neoatricon for pediatric critical care, received MHRA approval for UK market

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Collaboration to support ADC development and manufacturing, combining Piramal's payload-linker capabilities with Ajinomoto's biopharma expertise

4Blue-Zone Technologies Ltd.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-06
Description

Collaboration for capture, collection and recycling of waste anesthesia gas. Subject to regulatory approval, Blue-Zone will supply Phoenix Deltasorb system to PCC customers in France and Germany, while PCC processes captured anesthetic gas to produce Sevofluran USP for human use in Canada

piramalpharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Partnership expanding Piramal's payload-linker platform and bioconjugate capabilities through IntoCell's specialized technologies

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-22
Description

Investment in dedicated suite to enhance oral solid dosage production capabilities at Piramal's Sellersville, Pennsylvania site

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-03
Description

Integrated drug substance/drug product program for Bexagliflozin

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-03-23
Description

Master services agreement for investigational drug manufacturing for ongoing and planned clinical trials

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-21
Description

Sterile fill/finish program for TH1902 peptide-drug conjugate

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-08-27
Description

Exclusive integrated development and manufacturing program for orphan drugs

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-07-29
Description

Integrated development program for immune-stimulating antibody conjugates and sterile fill-finish

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-07-22
Description

Strategic partnership with US-based pharmaceutical outsourcing facility for critical care product distribution

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-20
Description

Acquisition of solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-12-03
Description

Collaboration on development of FDA Fast Track designated leukemia treatment

Recent move16 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Piramal Pharma

Pharmaceutical Manufacturing and CDMO Servicespiramalpharma.com

Piramal Pharma Limited is a global pharmaceutical company operating a CDMO (Piramal Pharma Solutions), an inhaled anesthetics and hospital generics business (Piramal Critical Care), and an India-focused OTC consumer healthcare division (Piramal Consumer Healthcare), serving pharma innovators, hospitals, and Indian consumers across 17 facilities in 100+ countries.

What Piramal Pharma does

Piramal Pharma Limited is a publicly listed (BSE/NSE ticker PPL) global pharmaceutical company headquartered in Mumbai, India, operating across four segments: Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a hospital generics and inhaled anesthetics franchise; Piramal Consumer Healthcare (PCH), an India-focused OTC business with brands such as Little's, Lacto Calamine, i-pill, Tetmosol, and Polycrol; and a joint venture with AbbVie in ophthalmic therapeutics.

The CDMO segment, which contributed approximately 55% of revenue, operates a network of 17 globally integrated development and manufacturing facilities across India, the United States, the United Kingdom, and Canada, offering end-to-end services from API synthesis and peptide manufacturing through formulation development and sterile fill-finish. Differentiated technical capabilities include the ADCelerate platform for accelerated antibody-drug conjugate (ADC) development, the Grangemouth UK facility — the first FDA-approved ADC CDMO globally with 1,500 batches delivered — specialized payload-linker manufacturing at Riverview, Michigan, Band 5 HPAPI containment, and proprietary digital platforms (eLab, exForms, iAssist) supported by an enterprise-wide Project Catalyst NxGen ERP transformation.

The company generates revenue through contract-based development fees and commercial supply agreements in CDMO, hospital-channel sales of generics and anesthetics in Critical Care, and Indian retail/e-commerce distribution in Consumer Healthcare. FY26 disclosed revenue was ₹8,869 crore, with management publicly targeting a doubling to approximately $2 billion by FY30. Key customers disclosed include Botanix SB Inc., NewAmsterdam Pharma, Plus Therapeutics, Bolt Biotherapeutics, Theracosbio, and Theratechnologies, alongside strategic co-development partnerships with Ajinomoto Bio-Pharma, IntoCell, and Blue-Zone Technologies.

Piramal Pharma firmographics

Firmographics
Name
Piramal Pharma
Legal name
Piramal Pharma Limited
Website
https://piramalpharma.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Piramal Pharma Limited is a global pharmaceutical company operating a CDMO (Piramal Pharma Solutions), an inhaled anesthetics and hospital generics business (Piramal Critical Care), and an India-focused OTC consumer healthcare division (Piramal Consumer Healthcare), serving pharma innovators, hospitals, and Indian consumers across 17 facilities in 100+ countries.
Ownership category
akta.pro rank

Piramal Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing and CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Contract pharmaceutical manufacturing
  • Drug development services
  • Inhaled anesthetics
  • Consumer healthcare products
  • Antibody drug conjugates

Where Piramal Pharma is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices18 records

Markets served

Piramal Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharma Solutions (CDMO): Contract Development and Manufacturing Organization providing end-to-end drug development and manufacturing services to pharmaceutical innovators. Revenue generated through service contracts, development fees, and commercial manufacturing supply agreements. Represents the largest revenue segment at approximately 55% of total revenue.
  2. Critical Care: Hospital generics business focused on inhaled anesthetics and critical care medications. Products sold to hospitals and healthcare facilities globally through direct sales and distribution partnerships.
  3. Consumer Healthcare: India-focused consumer healthcare business with established OTC brands including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri-Activ. Revenue from product sales through retail distribution channels.
  4. Complex Hospital Generics: Complex hospital generics including injectables and specialized pharmaceutical products. Growth segment including the Kenalog brand acquisition for hospital-based therapies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Piramal Pharma product offering

Product offering

Core offering

Piramal Pharma is a global integrated pharmaceutical company providing end-to-end contract development and manufacturing (CDMO) services, critical care pharmaceuticals including inhalation anesthetics and injectables, and consumer healthcare OTC products. The company serves top 20 biopharma companies, global hospital networks, and retail consumers through 17 manufacturing facilities across India, the US, the UK, and Canada.

Product overview

Piramal Pharma Limited operates as a diversified global pharmaceutical company with four distinct business segments: Piramal Pharma Solutions (PPS) as a Contract Development and Manufacturing Organization offering end-to-end drug development and manufacturing services; Piramal Critical Care (PCC) specializing in inhaled anesthetics and hospital generics; Piramal Consumer Healthcare (PCH) with established OTC brands including Little's, Lacto Calamine, i-pill, Tetmosol, Polycrol, Tri-Activ, and i-choose; and AbbVie Therapeutics India for ophthalmic products. The company also operates the ADCelerate platform for rapid integrated ADC development. PPS maintains facilities across North America, Europe, and Asia, providing services from API synthesis through finished dosage manufacturing, with digital platforms including eLab, exForms, and iAssist supporting quality and compliance operations.

Differentiator

Problem solved

Functional benefit

Brands

  • Piramal Pharma Solutions: Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug lifecycle
  • Piramal Critical Care
  • Piramal Consumer Healthcare
  • AbbVie Therapeutics India

Products and services

  • Piramal Pharma Solutions (CDMO Services) End-to-end contract development and manufacturing organization (CDMO) services for global biopharma companies, covering drug substance and drug product development, manufacturing, and commercialization across small molecules, biologics, and antibody-drug conjugates. Customers include top 20 biopharma companies.
  • Piramal Critical Care Critical care pharmaceutical products including inhalation anesthetics and injectable products sold to hospitals, healthcare institutions, and government health systems globally. The company is among the global leaders in inhalation anesthesia products.
  • Piramal Consumer Healthcare Over-the-counter (OTC) consumer healthcare and personal care brands sold through retail pharmacy chains and modern trade in India, including established brands such as Lacto Calamine and Jungle Magic.
  • AbbVie Therapeutics India (Joint Venture) Joint venture with AbbVie for the sale and distribution of AbbVie's pharmaceutical products in the Indian market, leveraging Piramal's established India sales and distribution infrastructure.

Quantifiable outcome

  • Delivered over 70 regulatory approvals across global network in single fiscal year
  • +4 more outcomes

Companies that use Piramal Pharma

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Piramal Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Piramal Pharma partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Botanix SB Inc.coreStrategic or Co-development Partner · 20 May 2026Manufacturing and supply arrangement to develop and validate Sofpironium Bromide at Piramal's Riverview, Michigan facility with optional validation at its Aurora, Canada facility
  • BrePco BiopharmaminorStrategic or Co-development Partner · 18 May 2026Joint development of Neoatricon for pediatric critical care, received MHRA approval for UK market
  • Ajinomoto Bio-Pharma ServicescoreStrategic or Co-development Partner · 16 April 2026Collaboration to support ADC development and manufacturing, combining Piramal's payload-linker capabilities with Ajinomoto's biopharma expertise
  • Blue-Zone Technologies Ltd.minorStrategic or Co-development Partner · 6 February 2026Collaboration for capture, collection and recycling of waste anesthesia gas. Subject to regulatory approval, Blue-Zone will supply Phoenix Deltasorb system to PCC customers in France and Germany, while PCC processes captured anesthetic gas to produce Sevofluran USP for human use in Canada
  • IntoCellcoreStrategic or Co-development Partner · 30 October 2025Partnership expanding Piramal's payload-linker platform and bioconjugate capabilities through IntoCell's specialized technologies
  • NewAmsterdam PharmacoreStrategic or Co-development Partner · 22 August 2025Investment in dedicated suite to enhance oral solid dosage production capabilities at Piramal's Sellersville, Pennsylvania site
  • TheracosbiominorStrategic or Co-development Partner · 3 April 2023Integrated drug substance/drug product program for Bexagliflozin
  • Plus Therapeutics, Inc.minorStrategic or Co-development Partner · 23 March 2021Master services agreement for investigational drug manufacturing for ongoing and planned clinical trials
  • Theratechnologies Inc.minorStrategic or Co-development Partner · 21 January 2021Sterile fill/finish program for TH1902 peptide-drug conjugate
  • Epirium BiominorStrategic or Co-development Partner · 27 August 2020Exclusive integrated development and manufacturing program for orphan drugs
  • Bolt BiotherapeuticsminorStrategic or Co-development Partner · 29 July 2020Integrated development program for immune-stimulating antibody conjugates and sterile fill-finish
  • Medivant HealthcareminorStrategic or Co-development Partner · 22 July 2020Strategic partnership with US-based pharmaceutical outsourcing facility for critical care product distribution
  • G&W Laboratories Inc.coreStrategic or Co-development Partner · 20 June 2020Acquisition of solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.
  • BerGenBiominorStrategic or Co-development Partner · 3 December 2019Collaboration on development of FDA Fast Track designated leukemia treatment

Scale indicators14 records

Recent moves16 records

Expansion highlights6 records

Piramal Pharma competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Piramal Pharma social profiles

Digital presence

Piramal Pharma compliance and trust

Trust signal

Compliance10 records

Piramal Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Piramal Pharma leadership team

Management profile

Number of profiles

Piramal Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Piramal Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Piramal Pharma M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Piramal Pharma

What does Piramal Pharma do?

Piramal Pharma is a global integrated pharmaceutical company providing end-to-end contract development and manufacturing (CDMO) services, critical care pharmaceuticals including inhalation anesthetics and injectables, and consumer healthcare OTC products. The company serves top 20 biopharma companies, global hospital networks, and retail consumers through 17 manufacturing facilities across India, the US, the UK, and Canada.

Is Piramal Pharma a public or private company?

Piramal Pharma is a public company. It is classified as public and is currently operating.

When was Piramal Pharma founded?

Piramal Pharma was founded in 2020. It employs 1,001 to 5,000 people.

Where is Piramal Pharma based?

Piramal Pharma is headquartered in Mumbai, India, in the Asia region.

How does Piramal Pharma make money?

Four revenue lines are on record. Pharma Solutions (CDMO) is the primary driver. The others are critical Care, consumer Healthcare and complex Hospital Generics.

Does Piramal Pharma have an API?

No public API is recorded for Piramal Pharma.

What industry is Piramal Pharma in?

Piramal Pharma's product category is Pharmaceutical Manufacturing and CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewPiramal Pharma to acquire remaining 26% stake in Yapan BioPiramal Pharma's board approved acquiring the remaining 26% stake in Yapan Bio, a vaccine and biologics CDMO subsidiary. The acquisition terms are not yet finalised, but Piramal's shareholding would rise from 74% to 100%.The HinduPiramal Pharma to acquire remaining 26% stake in Yapan BioPiramal Pharma's board approved acquiring the remaining 26% stake in Yapan Bio, raising its holding to 100%. Discussions on terms are ongoing, and Yapan will become a wholly owned subsidiary. The CDMO specializes in vaccine and biologics manufacturing.ET NOWStocks to watch today, November 19: Bharat Forge, Jio Financial Services, Infosys, Piramal Pharma, and othersBharat Forge, Jio Financial Services, Infosys, Piramal Pharma, and others are key stocks for November 19 trading. Bharat Forge invested Rs 291 crore in its subsidiary, Jio Financial Services invested Rs 123 crore in its BlackRock JV, and Piramal Pharma acquired the remaining stake in Yapan Bio. Infosys will invest 1.59 billion yen in NTT Docomo Playspace.ScanXPiramal Pharma exercises call option to acquire balance 26% in Yapan BioPiramal Pharma exercised its call option to acquire the remaining 26% stake in Yapan Bio, raising its holding from 74% to 100%. The transaction's final consideration and transfer date are yet to be finalized, with Piramal Pharma to disclose under SEBI regulations.TradingViewBroader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% eachBroader Indian equity markets outperformed the Nifty 50 during the week ended October 30, with the Sensex rising 1.82% and the Nifty 2%. Midcap and smallcap indices gained 2.7% and 4% respectively, driven by buying interest in sectors like pharma and media. FIIs turned net buyers with purchases of Rs 6,304 crore, while DIIs added Rs 3,109 crore.WhalesbookNifty Pharma Hits Record High As CDMO Stocks Lead GainsThe Nifty Pharma index hit a record 27,263.95 on Friday, driven by CDMO stocks like Laurus Labs, Sun Pharma, and Piramal Pharma. Laurus Labs rose 6% to ₹2,385.80, Sun Pharma climbed 5% on USFDA approval for ILUMYA, and Piramal Pharma raised its FY2027 revenue growth guidance to 19-20%. Investors should watch execution of project pipelines and regulatory risks.WhalesbookLaurus, Piramal Pharma Outpace Rivals As CDMO Demand SurgesIndian CDMOs Laurus Labs and Piramal Pharma reported September-quarter revenue growth of 33% and 28% respectively, driven by a recovery in global biotech spending. Piramal added 22 new customers and raised differentiated services revenue to 43%, while Laurus invested nearly 20% of revenue in new facilities. Investors will watch order-book conversion and facility utilization.Business News TodayMoneycontrol Pro Panorama | Indian pharma’s bright spot- Moneycontrol.comLaurus Labs and Piramal Pharma reported strong September quarter results, with revenues up 33% and 28% respectively, while finished dosage drug makers saw declines. CDMO growth is driven by new customers and pipeline, with Piramal adding 22 customers and Laurus seeing a 75% CDMO revenue jump. Analysts expect continued CDMO momentum as new capacity ramps up.Business StandardNifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%Nifty Pharma index hit a record high of 27,263.95, up over 2% on Friday, with Laurus Labs, Sun Pharma, and others rallying. Laurus Labs surged 6% on strong Q2 earnings, while Sun Pharma reported 4.8% EBITDA growth and received USFDA approval for ILUMYA for psoriatic arthritis. Piramal Pharma also rose 4% after lifting its FY27 outlook.PR NewswirePiramal Pharma Limited annonce ses résultats pour le deuxième trimestre et le premier semestre de l'exercice 2027Piramal Pharma reported Q2 and H1 FY27 results, with revenue up 28% and 23% year-on-year, and BAIIA margin expanding over 350 basis points. The company raised FY27 revenue growth guidance to 19-20% and expects a stronger second half.